Replacement therapy for hereditary alpha1-antitrypsin deficiency: A program for long-term administration

A. F. Barker, F. Siemsen, D. Pasley, R. D'Silva, A. S. Buist

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


This retrospective chart review describes the efficacy and safety of long- term administration of intravenous alpha1-antitrypsin (AAT) in 14 patients with hereditary AAT deficiency and COPD. During the 12- to 48-month observation period, 12 of 14 patients had stabilization of functional status; 4 patients had reductions in hospitalizations. Thirteen of 14 patients had no decline in pulmonary function. Three patients had self-limited adverse reactions to the AAT with one patient requiring a brief hospitalization.

Original languageEnglish (US)
Pages (from-to)1406-1410
Number of pages5
Issue number5
StatePublished - Jan 1 1994

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Replacement therapy for hereditary alpha<sub>1</sub>-antitrypsin deficiency: A program for long-term administration'. Together they form a unique fingerprint.

Cite this